To recover your password please fill in your email address
Please fill in below form to create an account with us
A tool for health care professionals and researchers to prognosticate progression-free survival outcomes in patients with BRCA mutation positive platinum-sensitive recurrent ovarian cancer about to commence with maintenance olaparib therapy
The NHMRC Clinical Trials Centre (CTC) strives to keep information stored in the PSROC Online tool up to date, but does not guarantee the accuracy, reliability or currency of the information. Any errors in the information that are brought to our attention will be corrected as soon as possible. The CTC reserves the right to change at any time without notice any information stored in the PSROC Online tool.
| CA-125 at commencement of Olaparib | options: <=25 IU/ml, >25 IU/ml |
| Platinum-free interval | options: 6-12 months, >12 months |
| Presence of disease >=1cm | options: No, Yes |
| Number of previous platinum lines | options: 2, >2 |
These results below provide a guide to inform discussions about progression-free survival (PFS) outcomes for your patients. The results are estimated using data from a group of selected patients enrolled in clinical trials. Caution should be exercised when interpreting these results as your patients may be different from the clinical trial patients.
|
|